Melane Sampson, Author at BioTuesdays

Developments

Cereno reports positive data from CS1 treatment in PAH

Cereno Scientific (NASDAQ First North: CRNO B) has announced initial learnings from its 12-month expanded access program with lead candidate, oral, once-daily CS1, in pulmonary arterial hypertension (PAH), confirming...

March 31, 2026

Developments

BioVersys enters agreement with HMH to develop ansamycin

BioVersys (SIX: BIOV) has entered into an exclusive ansamycin drug discovery collaboration and license agreement with Hackensack Meridian Health (HMH), a U.S.-based private nonprofit health system, to jointly profile...

March 31, 2026

Developments

Idorsia highlights positive results from study of DORA in pediatric patients with insomnia

Idorsia (SIX: IDIA) has announced positive top-line results from its Phase 2 dose-finding study evaluating 10, 25, and 50 mg doses of daridorexant—the company’s dual orexin receptor antagonist (DORA)—in pediatric...

March 30, 2026

Executive Moves

Dr. Raj S. Pruthi joins PreveCeutical’s BOD

PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF; FSE: 18H0) has appointed Raj S. Pruthi, MD, MHA, FACS, to its board of directors (BOD). Dr. Pruthi currently serves as CMO of Relmada Therapeutics. An accomplished...

March 30, 2026

Developments

FDA grants accelerated approval of Rocket’s KRESLADI for pediatric LAD-I

Rocket Pharmaceuticals (NASDAQ: RCKT) has announced FDA approval of KRESLADI, an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion...

March 27, 2026

Developments

FDA clears Lantern/Starlight’s IND for trial of STAR-001 in pediatric cancer

Lantern Pharma (NASDAQ: LTRN) and its subsidiary, closely held Starlight Therapeutics, have announced FDA clearance of the investigational new drug (IND) application for STAR-001, in a planned Phase 1 pediatric clinical...

March 27, 2026

Developments

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure performed in Dallas Medical Center’s state-of-the-art MRI suite. “Having...

March 27, 2026

Developments

NextPlat expands reach through collaboration with HealthWarehouse.com

NextPlat (NASDAQ: NXPL; NXPLW) has announced a collaboration with HealthWarehouse.com (OTCQB: HEWA) to enable nationwide fulfillment of prescription and over-the-counter (OTC) products. According to NextPlat, the...

March 26, 2026

Executive Moves

Wang Haijiao joins Fangzhou as CEO

Fangzhou (HKEX: 06086) has announced the appointment of Wang Haijiao as chief executive officer (CEO) and executive director, effective today. Mr. Wang’s nearly 20 years of extensive healthcare industry experience in...

March 26, 2026

Developments

Firefly confirms public-private partnership with DoW

Firefly Neuroscience (NASDAQ: AIFF) has announced a partnership with the Department of War (DoW) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from post-traumatic...

March 26, 2026

Author - Melane Sampson

Cereno reports positive data from CS1 treatment in PAH

BioVersys enters agreement with HMH to develop ansamycin

Idorsia highlights positive results from study of DORA in pediatric patients with insomnia

Dr. Raj S. Pruthi joins PreveCeutical’s BOD

FDA grants accelerated approval of Rocket’s KRESLADI for pediatric LAD-I

FDA clears Lantern/Starlight’s IND for trial of STAR-001 in pediatric cancer

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

NextPlat expands reach through collaboration with HealthWarehouse.com

Wang Haijiao joins Fangzhou as CEO

Firefly confirms public-private partnership with DoW

Subscribe